Discovery Laboratories Inc (DSCO)

1.77
0.03 1.61
NASDAQ : Health Care
Prev Close 1.80
Open 1.82
Day Low/High 1.70 / 1.82
52 Wk Low/High 1.42 / 8.12
Volume 12.44K
Avg Volume 94.60K
Exchange NASDAQ
Shares Outstanding 8.19M
Market Cap 31.62M
EPS -7.25
P/E Ratio N/A
Div & Yield N.A. (N.A)

Bruce A. Peacock Joins Discovery Labs' Board Of Directors

Seasoned Executive With Proven Track Record Building Leading Biotech Companies; Significant Experience Advancing Development Programs Into Commercial Products

Discovery Labs Announces Conference Call

Small-Caps Put on Nasdaq Chopping Block

Small-Caps Put on Nasdaq Chopping Block

Thirteen companies received Nasdaq delisting notices in December and still fail to meet exchange requirements.

Biotech Stock Mailbag: Spectrum Pharma

Biotech watchdog Adam Feuerstein answers readers' questions about drug and health care companies.

Stock Offerings: Sino Clean Energy

Sino Clean Energy will offer up to $35 million in common stock.

Discovery Labs, FelCor: Volume Movers

Several stocks, including Discovery Labs, were poised to move on above-average volume Thursday.

Discover Laboratories, Alloy: Early Volume Plays

Several stocks trading near $5, including Discovery Laboratories, were poised to move on above-average volume Wednesday.

Discovery Labs Receives FDA Guidance Regarding Preclinical Program To Gain Surfaxin(R) Approval

On-Track for Q1 2011 Surfaxin Complete Response Filing

Discovery Labs Achieves Key Milestone Towards Potential Surfaxin(R) Approval

Biological Activity Test (BAT) Optimization and Revalidation Completed With All Pre-Specified Acceptance Criteria Met

Discovery Labs' KL4 Surfactant Demonstrates Potential Protective Role For Lung Transplantation In Established Preclinical Model

Data Presented at 2010 American Thoracic Society International Conference

Surfaxin LS(TM) Improves Pulmonary Function And Reduces Lung Inflammation In Established Model Of Respiratory Distress Syndrome

New Preclinical Data Presented at the 2010 Pediatric Academic Societies Annual Meeting

Discovery Labs Announces Conference Call

Earnings Roundup: Children's Place, Vail Resorts

Earnings roundup: Children's Place profit dips, sales rise; Vail Resorts profit falls

Biotech Stock Mailbag: Health Discovery

Biotech Stock Mailbag: Health Discovery

Our senior biotech columnist answers readers' questions about Health Discovery, Discovery Labs and other newsworthy healthcare stocks.

Biotech Stock Mailbag: FDA Playbook

Smart drug and biotech companies keep the FDA abreast of their clinical trial program throughout the long drug-development process.

Genzyme's Termeer: Worst Biotech CEO of '09

Genzyme's Termeer: Worst Biotech CEO of '09

Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009.

Discovery Labs: Pump Up the Volume

Discovery Labs: Pump Up the Volume

Discovery Laboratories slumped on a spike in volume days after an agreement with the Food and Drug Administration cleared a path for its experimental lung drug.

Discovery Labs: Pump Up the Volume

Discovery Labs: Pump Up the Volume

Discovery Laboratories jumped on a massive spike in volume Wednesday after it reached an agreement with the FDA that clears a path for its experimental lung drug.

Discovery Could Move Ahead With Surfaxin Program

Discovery Could Move Ahead With Surfaxin Program

Discovery Laboratories says potential FDA agreement means possible movement on lung drug